Table 2.

Clinical characteristics and EGFR mutation status in 22 responders to gefitinib

Country of originAgesexSmoking statusPatholPrior regimensResponseOverall survival (mo)Survival statusEGFR mutation 1 AA sequenceEGFR mutation 2 AA sequenceMutational status
Spain60FYesADC1PR6.7Dwtwt
Spain52FYesADC1PR8.3Dwtwt
Germany65MYesADC1PR22.1Dwtwt
Japan53FNoLCC3PR18.4Dwtwt
Japan76MYesADC3PR10.8Awtwt
Japan68FNoADC2PR24.3Dwtwt
Spain71FNoADC1PR8.9AdelE746_A750Hetero
Spain63MYesADC3PR17.8AdelE746_T751InsAHetero
Germany66FNoADC2PR13.7DdelE746_S752InsVHetero
China67MNoADC0PR22.0AdelL747_P753InsSL861QHetero
China34FNoADC2PR6.1AL858RHomo
China61FNoADC2PR14.3AL858RHetero
China49MYesADC1PR25.4AL858RHomo
China37MNoADC0PR15.9AdelE746_S752InsVHetero
Japan71FNoADC1PR14.2Adel719G(G)C to GCHetero
Japan66FNoADC0PR9.5AdelE746_T751Homo
Japan54FNoADC2PR18.7DdelE746_A750Homo
Japan60FNoADC3PR15.3AL718PHetero
Japan50MNoADC0PR18.4AdelL747_T751InsFHetero
Japan52MYesADC1PR8.9AdelE746_A750Homo
Japan42FNoADC2CR18.9AdelE746_A750Homo
USA84FNoADC1PR11.7DdelE746_A750Hetero
  • Abbreviations: Pathol, pathologic diagnosis; ADC, adenocarcinoma; LCC, large cell carcinoma; PR, partial response; CR, complete response; A, alive; D, dead; AA, amino acid; Homo, homozygogous; Hetero, heterozygous; wt, wild type.